The total return over the past 12 months is +23.28% vs. +16.94% for the S&P 500. So far it's up +51.30% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +23.28% | +18.33% | (18.54%) | (21.03%) | (8.68%) | (12.85%) |
| Total Return CAGR | +23.28% | +18.33% | (18.54%) | (21.03%) | (8.68%) | (12.85%) |
| Revenue CAGR | (29.03%) | +366.52% | +42.36% | (12.66%) | +18.66% | (3.52%) |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Lexicon Pharmaceuticals, Inc. (LXRX)
| Year | Start price | End price | LXRX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $1.15 | $1.74 | +51.30% | +14.51% | +36.79% |
| 2025 | $0.74 | $1.15 | +55.72% | +17.72% | +38.00% |
| 2024 | $1.53 | $0.74 | (51.73%) | +24.89% | (76.62%) |
| 2023 | $1.91 | $1.53 | (19.90%) | +26.19% | (46.09%) |
| 2022 | $3.94 | $1.91 | (51.52%) | (18.17%) | (33.35%) |
| 2021 | $3.42 | $3.94 | +15.20% | +28.74% | (13.54%) |
| 2020 | $4.15 | $3.42 | (17.59%) | +18.37% | (35.96%) |
| 2019 | $6.64 | $4.15 | (37.50%) | +31.22% | (68.72%) |
| 2018 | $9.88 | $6.64 | (32.79%) | (4.56%) | (28.23%) |
| 2017 | $13.83 | $9.88 | (28.56%) | +21.70% | (50.26%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
